Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26B1 | Q9NR63 | 4/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.35 |
| ▸ | DAO | P14920 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705920 | 0.85 | DAO (0.37) | CYP26B1CYP26A1DAOTSHRRXRA | |
| SCHEMBL1167677 | 0.78 | TSHR (0.31) | DAOTSHR | |
| SCHEMBL29599975 | 0.77 | PRSS1 (0.38) | DAO | |
| SCHEMBL21782417 | 0.77 | — | — | |
| SCHEMBL29088416 | 0.76 | CYP26A1 (0.34) | CYP26A1DAOCYP3A4RXRA | |
| SCHEMBL29600076 | 0.73 | LMNA (0.43) | CYP26B1CYP26A1FFAR1NPSR1CYP3A4 | |
| SCHEMBL29599669 | 0.72 | CYP26A1 (0.40) | CYP26B1CYP26A1FFAR1NPSR1CYP3A4 | |
| SCHEMBL2399697 | 0.71 | DAO (0.47) | FFAR1LTB4RDAONPSR1RXRA | |
| SCHEMBL1166919 | 0.70 | ALDH1A1 (0.32) | — | |
| SCHEMBL29088405 | 0.70 | RARB (0.35) | RXRAHCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| US-20230024995-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-3998262-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024995-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | CYP26B1 678/4885CYP26A1 1192/4885FFAR1 2030/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | CYP26B1 2350/4885CYP26A1 2603/4885FFAR1 2058/4885 |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | CYP26B1 541/4885CYP26A1 757/4885FFAR1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.